Participants in this group are nested in churches which were randomly assigned to the treatment group.

Participants in this group are nested in churches which were randomly assigned to the wait-list control group. They receive an educational luncheon focused on stress reduction during the intervention window for the Early Intervention group, and subsequently receive the intervention(s) for their selected target health behaviors at a later date.

Lung Cancer

Cervical Cancer

Breast Cancer

Colorectal Cancer

For smoking cessation: Cooper-Clayton group sessions plus motivational interviewing, both delivered by local lay health advisor.
For all cancer screenings: lay health advisor home visits incorporating motivational interviewing and focused on decreasing participant-identified barriers to screening.

Lay health advisor interactions

Faith Moves Mountains

Faith Moves Mountains: A Community Based Participatory Research (CBPR) Appalachian Wellness & Cancer Prevention Program

Faith Moves Mountains: A CBPR Appalachian Wellness & Cancer Prevention Program

For smoking cessation: Self-reported smoking status. For cancer screenings: Self-reported receipt of cervical, breast, and/or colorectal cancer screening. This assessment occurs after the Early Treatment group has completed the intervention.

Measured using reliable and valid instruments which were pretested in focus groups comprised of members of the target population. Positive change (i.e., increasing stage of readiness) from baseline to post-test will be coded as "1," while negative or no change will be coded "0." This assessment occurs after the Early Treatment group has completed the intervention.

This process measure will reflect the number of visits/classes attended by participants, as a means of assessing participation rate and feasibility.

Retention numbers will be assessed as a process measure outcome. Participants who complete all study assessment timepoints will be coded as "1," while participants who drop out will be coded "0." Number/percentage of participants who remained enrolled and complete all study procedures and assessments will be used as an indicator of feasibility in the community setting.

Nancy Schoenberg

Sponsor/PI

National Institute on Minority Health and Health Disparities (NIMHD)

Solid Tumor

Metastatic Colorectal Cancer

dasatinib

bevacizumab

Oxaliplatin

Capecitabine

Rocky Mountain Cancer Center

Duke Univeristy Medical Center

XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib

A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors With Expanded Cohort of Patients With Previously Untreated Metastatic Colorectal Cancer.

Herbert Hurwitz, MD

Associate Professor of Medicine

Bristol-Myers Squibb

Subdermal low (1.0 ml) or high (2.0 ml) dose injection of the ultrasound contrast agent Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around a 2 cm in diameter region in the mid-upper outer quadrant of the left breast, followed a week later by the other dose injected in the same fashion into the right breast.

Subdermal injection of the ultrasound contrast agent of Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around the breast cancer. Subjects will receive an injection of either a low (1.0 ml) or a high (2.0 ml) dose of Sonazoid depending on the outcome of the Part 1 safety and tolerability study.

subdermal injection into the breast of Sonazoid (1 or 2 ml) divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock)

Sonazoid; Perflubutane for Injection

Thomas Jefferson University

Contrast Ultrasound Detection of Sentinel Lymph Nodes

Contrast Ultrasound Detection of Sentinel Lymph Nodes in Breast Cancer Patients

To establish, in healthy, female volunteers, the optimal dose of subdermaly administrated Sonazoid (an ultrasound contrast agent) employed for contrast enhanced ultrasound imaging (CEUS)

To assess the safety and tolerability of subdermal administration of Sonazoid in 12 female, healthy volunteers.

To determine if CEUS of subdermally administrated Sonazoid (i.e., lymphosonography) identify more sentinel lymph nodes (SLNs) in patients with breast cancer compared to isotope mapping (with Tc-99m sulfur colloids) using blue dye and surgical dissection as the reference standard. The fundamental hypothesis is that on average lymphosonography will detect 3.2 SLNs compared to 2.7 with isotope mapping.

De-identified data will be made available to the research community upon request after the completion of the study in accordance with NIH rules and regulations.

Sidney Kimmel Cancer Center at Thomas Jefferson University

National Cancer Institute (NCI)

GE Healthcare

Siemens Medical Solutions

patients with biopsy or fnac proven ductal adenocarcinoma without any systemic metastatic spread at preoperative imaging

Pancreatic Cancer

K-RAS, CDKN2A, SMAD4 and TP53 mutation on circulating cfDNA

Liquid Biopsy

St Vincent university Hospital

Policlinico Universitario Agostino Gemelli

AOU Sant'Andrea - UOC Chirurgia Generale

Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis

Presence of venous and/or arterial invasion

local or systemic recurrence after resection

Presence of locoregional nodes' metastasis

Laura Antolino

University of Roma La Sapienza

Azienda Ospedaliero, Universitaria Pisana

Postmenopausal

Dual x-ray absorptiometry (DXA)

Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays

Blood draw

Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months
Cognitive tests - baseline, 6 months, 12 months
Depression assessment - baseline, 6 months, 12 months
Dietary calcium intake questionnaire - baseline

mountain/cancer mamar

Faith Moves Mountains: A Community Based Participatory Research (CBPR) Appalachian Wellness & Cancer Prevention Program

XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib

Contrast Ultrasound Detection of Sentinel Lymph Nodes

Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis

Effect of Aromatase Inhibitors on Bones and Genes

Cea mai completă bază de date cu plante medicinale susținută de știință